Key result
Periostin induces cartilage degradation by signaling through DDR1, and pharmacological inhibition or genetic deficiency of DDR1 significantly blocks Periostin-induced MMP-13 expression.
Why the study?
The cellular and molecular mechanisms of osteoarthritis progression and the relative contributions of cartilage, bone, and synovium remain unclear.
p-value: p=<0.05
Periostin promotes cartilage degeneration in osteoarthritis by signaling through DDR1 to activate AKT/β-catenin and upregulate MMP-13, identifying DDR1 as a potential therapeutic target.
Periostin-DDR1 signaling may promote OA cartilage loss; leaves open whether DDR1 inhibition alters disease course in patients.
Osteoarthritis (OA) is characterized by progressive loss of articular cartilage accompanied by the new bone formation and, often, a synovial proliferation that culminates in pain, loss of joint function, and disability. However, the cellular and molecular mechanisms of OA progression and the relative contributions of cartilage, bone, and synovium remain unclear. We recently found that the extracellular matrix (ECM) protein periostin (Postn, or osteoblast-specific factor, OSF-2) is expressed at high levels in human OA cartilage. Multiple groups have also reported elevated expression of Postn in several rodent models of OA. We have previously reported that in vitro Postn promotes collagen and proteoglycan degradation in human chondrocytes through AKT/β-catenin signaling and downstream activation of MMP-13 and ADAMTS4 expression. Here we show that Postn induces collagen and proteoglycan degradation in cartilage by signaling through discoidin domain receptor-1 (DDR1), a receptor tyrosine kinase. The genetic deficiency or pharmacological inhibition of DDR1 in mouse chondrocytes blocks Postn-induced MMP-13 expression. These data show that Postn is signaling though DDR1 is mechanistically involved in OA pathophysiology. Specific inhibitors of DDR1 may provide therapeutic opportunities to treat OA.
No takes yet. Share an insight, caveat, or question.
Han et al. (2020) studied Osteoarthritis. DDR1 inhibition (7rh) or genetic deficiency vs. Vehicle or wild-type was evaluated on MMP-13 expression and activity (p=<0.05). Periostin induces cartilage degradation by signaling through DDR1, and pharmacological inhibition or genetic deficiency of DDR1 significantly blocks Periostin-induced MMP-13 expression.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: